Trade TARS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Tarsus Pharmaceuticals, Inc. (TARS) is trading at US$78.09, down 1.19% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$3.19B. Over the past 52 weeks, TARS has traded between US$53.85 and US$91.53. On Syfe you can trade TARS with $0 commission and add it to your watchlist.
| Previous close | US$79.03 |
|---|---|
| Market cap | US$3.19B |
| P/E ratio | 154.45 |
| 52-week range | US$53.85 – US$91.53 |
| Volume | 689.68K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Year: 2020
Tarsus Pharmaceuticals, Inc. (TARS) stock is trading at US$78.09, -1.19% from the previous close of US$79.03.
The market cap for Tarsus Pharmaceuticals, Inc. (TARS) stock is approximately US$3.19B.
The price-to-earnings ratio for Tarsus Pharmaceuticals, Inc. (TARS) is 154.45, based on the latest reported earnings.
The 52-week high for Tarsus Pharmaceuticals, Inc. (TARS) stock is US$91.53.
The 52-week low for Tarsus Pharmaceuticals, Inc. (TARS) stock is US$53.85.
Tarsus Pharmaceuticals, Inc. (TARS) does not currently pay a dividend.
Stay on top of TARS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
